This week, Alnylam announced that its Ribopharma unit has granted a non-exclusive license to the Kreutzer-Limmer patent, a European patent that covers “a medicament containing at least one double-stranded oligonucleotide (dsRNA) designed to inhibit the expression of a target gene,” to RNAx.

Under the deal, RNAx has the right to use the technology covered by the patent to provide research services. In exchange, Ribopharma will receive upfront and annual license fees, as well as royalties on revenues derived from licensed services.